Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away

Core Viewpoint - Pfizer's CEO indicates that tariffs and uncertainty from the Trump administration are hindering the company's ability to make significant investments in the US [1][2]. Group 1: Impact of Tariffs on Investments - CEO Albert Bourla stated that the absence of tariffs and a stable environment would enable Pfizer to make "tremendous investments" in both R&D and manufacturing in the US [2]. - Bourla emphasized that during uncertain times, companies, including Pfizer, are controlling costs and being "very frugal" with investments to remain prepared for any eventualities [2]. - Pfizer currently operates 13 manufacturing sites in the US, which are functioning at good capacity, but the company is prepared to transfer manufacturing from overseas sites if necessary [3]. Group 2: Financial Implications of Tariffs - Pfizer's finance chief, Dave Denton, projected that the existing tariffs would cost the company approximately $150 million by 2025 [4]. - Although pharmaceutical products were initially exempt from the 10$1 billion commercial production facility in Delaware, highlighting its commitment to US manufacturing [7]. - Investor Mark Cuban warned that drug prices from his company could rise if tariffs on India are enforced [7].